LOUGHBOROUGH, England (October 14, 2019) – Science World, the Fisher Scientific Laboratory Experience, made a successful debut at Leicester Tigers Rugby Club on 10 October. The event, hosted by Thermo Fisher Scientific, showcased the latest in laboratory innovations available through the Fisher Scientific channel. Thousands of products were available for attendees to experience, making it an ideal event for anyone working in or around a laboratory.
News
AMSBIO announces two new Luciferase assay kits designed to help you improve your gene reporter assays.
Cambridge, UK – 16 October, 2019 – Healx, the AI-powered and patient-inspired technology company specialising in treatments for rare diseases, today announces that it has raised $56 million in a Series B financing round, led by one of Europe’s largest VC firms Atomico and joined by Intel Capital, Global Brain and btov Partners. All previous investors, including Balderton Capital, Amadeus Capital Partners, and Jonathan Milner also participated in the round.
Cambridge, UK, 14th October 2019: Mogrify Ltd (Mogrify), a UK company aiming to transform the development of life-saving cell therapies, today announced the initial close of its Series A funding. The Company raised $16 million USD in this round, bringing the total investment to over $20 million USD to date. The funding will support internal cell therapy programs, and the development and out-license of novel IP relating to cell conversions of broad therapeutic interest.
Clinical Professionals fully fund and train some of the UK’s brightest life science graduates with the aim of giving back and assisting in the future of the industry talent pool and future skilled professionals.
Reading Scientific Services Ltd (RSSL) secures Enlighted Employer Award in recognition of its exceptional commitment to gender equality in the workplace.
Nadhim Zahawi MP has announced that Stevenage Bioscience Catalyst (SBC) has been successful in its application to become a Life Science Opportunity Zone.
The assessment panel consisted of senior industry life science experts and senior government officials. In a letter to Stevenage Bioscience Catalyst Chief Executive Officer Dr Sally Ann Forsyth, the Minister stated: “l am delighted to tell you that your application has been successful. The panel were impressed by your plans to grow what is already a successful biomedical campus.”
Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces completion of dosing and all patient visits in its Phase I clinical trial for its ultra-rapid acting insulin product candidate, AT247.